Dr. Reddy's Laboratories Announces the Launch of a Generic Version of Sapropterin Dihydrochloride Tablets for Oral Use in the U.S. MarketBusiness Wire • 10/03/20
Dr. Reddy's Laboratories Announces the Launch of Cinacalcet Tablets in the U.S. MarketBusiness Wire • 10/01/20
Dr. Reddy's Laboratories Announces the Launch of Dimethyl Fumarate Delayed-Release Capsules in the U.S. MarketBusiness Wire • 09/26/20
Dr. Reddy's announces the launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in the U.S. MarketBusiness Wire • 09/25/20
Dr. Reddy's Laboratories announces settlement of U.S. Revlimid® (lenalidomide) Capsules patent litigation with Celgene, a Bristol Myers Squibb CompanyBusiness Wire • 09/17/20
Bristol Myers Squibb Announces Settlement of U.S. Patent Litigation for REVLIMID® (lenalidomide) With Dr. Reddy’sBusiness Wire • 09/17/20
Dr. Reddy’s announces the launch of Over-the-Counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% and 0.1%, the store-brand equivalent of Pataday®, the Eye Allergy Drop in the U.S. MarketBusiness Wire • 09/17/20
India Pharma Inks Supply, Clinical Trials Pact For Russia's Sputnik Coronavirus VaccineInvestors Business Daily • 09/16/20
Russia to provide Indian drug company Dr. Reddy's with 100 million doses of its COVID-19 vaccineMarket Watch • 09/16/20
RDIF and Dr. Reddy’s to cooperate on clinical trials and supply of 100 million doses of Sputnik V vaccine to IndiaBusiness Wire • 09/16/20
Dr. Reddy's Laboratories announces the launch of Over-The-Counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren® Arthritis Pain in the U.S. MarketBusiness Wire • 09/09/20
Dr. Reddy's Laboratories Announces the Launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single-Dose Syringe in the U.S. MarketBusiness Wire • 09/07/20
Dr. Reddy's Laboratories announces the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, in the U.S. MarketBusiness Wire • 09/03/20
Dr. Reddy's Laboratories announces the launch of Penicillamine Capsules USP, 250 mg in the U.S. MarketBusiness Wire • 08/27/20
Dr. Reddy's Laboratories announces the launch of AVIGAN® (Favipiravir) in IndiaBusiness Wire • 08/19/20
Dr. Reddy's Laboratories announces the First-to-Market launch of the generic version of Ciprodex® (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, USP in the U.S. MarketBusiness Wire • 08/11/20
Dr. Reddy's Laboratories' (RDY) CEO Erez Israeli on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 07/30/20